FDA advisors strongly back new Alzheimer’s drug, despite risks and limitations

Posted
Advisors to the Food and Drug Administration have recommended unanimously that the agency approve the Alzheimer’s drug donanemab.(Image credit: Andrew Harnik)

Continue reading at NPR:Shots - Health News »